Glaukos (NYSE:GKOS) yesterday posted first quarter 2019 earnings that topped both loss per share and sales expectations on Wall Street. The San Clemente, Calif.-based company posted losses of $1.3 million, or 4¢ per share, on sales of approximately $54 million for the three months ended March 31, seeing losses shrink 50.5% while sales grew 34.6% when […]
Glaukos, Santen ink U.S. MicroShunt distro deal
Glaukos (NYSE:GKOS) said last Friday that it inked a multi-year distribution deal with Santen Pharmaceutical (OTC:SNPHY) to market its MicroShunt device, intended to reduce intraocular pressure in patients with primary open-angle glaucoma (POAG), in the U.S. Through the deal, San Clemente, Calif.-based Glaukos will become the exclusive U.S. distributor of the MicroShunt, which is being studied in […]
Glaukos touts 5-year study of glaucoma stents
Glaukos (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said. The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two […]
Ivantis touts 2-year Hydrus, Glaukos iStent head-to-head study results
Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting reductions in medication use and no reoperations for patients in the Hydrus arm. The Irvine, Calif.-based company said that it is presenting results from the Compare trial today at the American Glaucoma Society’s annual meeting in […]
Glaukos rises on Street-beating Q4, 2018 earnings
Shares in Glaukos (NYSE:GKOS) are rising today after the ophthalmological-focused medical device maker posted fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The San Clemente, Calif.-based company posted profits of approximately $1.8 million, or 4¢ per share, on sales of approximately $54.1 million for the three months ended December 31, for […]
Glaukos inks R&D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. Get the full story at our sister site, Drug Delivery […]
Glaukos shares fall on mixed-bag Q2
Shares in Glaukos (NYSE:GKOS) have fallen today after the ophthalmological device maker topped Wall Street sales consensus but missed on loss-per-share expectations with its second quarter earnings results. The San Clemente, Calif.-based company posted losses of $5.4 million, or 15¢ per share, on sales of $43.2 million for the three months ended June 30, seeing losses grow 63.5% […]
Glaukos wins FDA PMA for iStent inject glaucoma device
Glaukos (NYSE:GKOS) said today it won FDA premarket approval for its iStent inject trabecular micro-bypass system. With the clearance, the iStent inject is now indicated for use in the reduction of intraocular pressure in adults with mild to moderate primary open-angle glaucoma who are undergoing concomitant cataract surgery. San Clemente, Calif.-based Glaukos said the iStent […]
Glaukos posts red ink in Q1 earnings
Shares in Glaukos (NYSE:GKOS) have fallen today after the ophthalmic medical tech company posted first quarter earnings that saw profits swing to losses, despite topping The Street’s expectations. The San Clemente, Calif.-based company posted losses of $2.7 million, or 8¢ per share, on sales of $40.1 million for the three months ended March 31, seeing an […]
Ivantis touts 1-year head-to-head Hydrus, Glaukos iStent study data
Ivantis today released one-year results from the study of its Hydrus Microstent comparing it to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting the Hydrus’ ability to reduce reliance on medication and intraocular pressure. Results from the trial were presented at the American Society of Cataract and Refractive Surgery annual meeting in Washington D.C. by Dr. David […]
Glaukos touts 2-year iStent inject pivotal trial data, levies infringement suit against Ivantis
Glaukos (NYSE:GKOS) today released two-year data from the FDA investigational device exemption pivotal trial of its iStent inject trabecular micro-bypass system, and announced a patent infringement suit it filed against Ivantis. Results of the 505-patient study were presented at the American Society of Cataracts and Refractive Surgery annual meeting by Dr. Thomas Samuelson of the Minnesota Eye […]
- 1
- 2
- 3
- …
- 5
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube